Predicted dolutegravir resistance in people living with HIV in South Africa during 2020-35: a modelling study.

Saved in:
Bibliographic Details
Title: Predicted dolutegravir resistance in people living with HIV in South Africa during 2020-35: a modelling study.
Authors: Loosli T; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland., Han N; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland., Hauser A; Department of Epidemiology and Health Systems, Unisanté, Center for Primary Care and Public Health and University of Lausanne, Lausanne, Switzerland., Josi J; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland., Ingle SM; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK., van Sighem A; Stichting HIV Monitoring, Amsterdam, Netherlands., Wittkop L; Bordeaux Population Health U1219, Université de Bordeaux, Institut National de la Santé et de la Recherche Médicale, Bordeaux, France; Statistics in System Biology and Translational Medicine, National Institute for Research in Digital Science and Technology, Bordeaux, France; Service d'information Médicale, Centre d'Investigation Clinique-Epidémiologie Clinique 1401, Centre Hospitalier Universitaire de Bordeaux, Institut National de la Santé et de la Recherche Médicale, Bordeaux, France., Vehreschild J; Institute for Digital Medicine and Clinical Data Sciences, Goethe University, Frankfurt, Germany; Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany; German Centre for Infection Research, Cologne, Germany., Ceccherini-Silberstein F; Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy., Maartens G; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa., Gill MJ; Southern Alberta Clinic, Calgary, AB, Canada; Department of Medicine, University of Calgary, Calgary, AB, Canada., Sabin CA; Institute for Global Health, University College London, London, UK., Johnson LF; Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa., Lessells R; KwaZulu-Natal Research Innovation and Sequencing Platform, University of KwaZulu-Natal, Durban, South Africa; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa., Günthard HF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland., Egger M; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland., Kouyos RD; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; Institute of Medical Virology, University of Zurich, Zurich, Switzerland. Electronic address: roger.kouyos@uzh.ch.
Source: The Lancet. Global health [Lancet Glob Health] 2025 Apr; Vol. 13 (4), pp. e698-e706.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101613665 Publication Model: Print Cited Medium: Internet ISSN: 2214-109X (Electronic) Linking ISSN: 2214109X NLM ISO Abbreviation: Lancet Glob Health Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2214-109X
DOI:10.1016/S2214-109X(24)00553-9